dpp 4 inhibitors glp 1 dpp-4_inhibitors [TUSOM GLP 1 Receptor Agonists and
Description
Across studies, fat mass decline predominated, whereas reductions in lean body mass were modest

Results show broad benefits with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions

no major safety concerns were observed

Plant-based, designed to support energy and supports a healthy daily routine

The GLP-1 Market size was valued at USD 52.82 billion in 2025 and is expected to grow at a CAGR of 10.9% from 2026 to 2034.
Cited in 37 publications
